4.30
Schlusskurs vom Vortag:
$4.31
Offen:
$4.33
24-Stunden-Volumen:
842.44K
Relative Volume:
0.73
Marktkapitalisierung:
$319.18M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-25.06
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
+10.26%
1M Leistung:
+24.28%
6M Leistung:
+19.44%
1J Leistung:
-66.97%
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Vergleichen Sie CATX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CATX
Perspective Therapeutics Inc
|
4.30 | 289.49M | 6.96M | -46.51M | -37.99M | -0.1716 |
![]()
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
2024-10-24 | Eingeleitet | UBS | Buy |
2024-10-01 | Eingeleitet | Wedbush | Outperform |
2024-09-25 | Eingeleitet | Truist | Buy |
2024-07-25 | Eingeleitet | BofA Securities | Buy |
2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
What drives Perspective Therapeutics Inc. stock priceUnmatched profit potential - jammulinksnews.com
Is Perspective Therapeutics Inc. a good long term investmentHigh-margin investment plays - jammulinksnews.com
What analysts say about Perspective Therapeutics Inc. stockHigh-velocity capital appreciation - jammulinksnews.com
Perspective Therapeutics Inc. Stock Analysis and ForecastExtraordinary performance - Autocar Professional
Why Perspective Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
How Perspective Therapeutics Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
What makes Perspective Therapeutics Inc. stock price move sharplyHigh Return Setup Scanner - Newser
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results - The Manila Times
Cancer Treatment Pioneer Perspective Therapeutics Announces Q2 2025 Earnings Date: Key Updates Coming - Stock Titan
Top Reasons to Buy SBT(sbtcoin)Free Stock Market Practical Discussion Forums - newser.com
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
Perspective Therapeutics Updates Strategic Focus on Radiopharmaceuticals - TipRanks
Perspective Therapeutics, Inc.(NYSEAM: CATX) dropped from Russell 3000 Growth Index - MarketScreener
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Perspective Therapeutics (CATX) and Codexis (CDXS) - The Globe and Mail
Perspective Therapeutics (CATX) Maintains 'Outperform' Rating by Wedbush | CATX Stock News - GuruFocus
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial - Yahoo Finance
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - Finansavisen
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE - Defense World
Analyzing Ratios: Perspective Therapeutics Inc (CATX)’s Financial Story Unveiled - DWinneX
New Research Reveals Top 6 Radioligand Therapy Companies Transforming Cancer Treatment in $13B Market - Stock Titan
The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic - insights.citeline.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Warren Buffett Says Buy This Index Fund, and Here's How It Could Turn $500 Per Month Into $1 Million - The Globe and Mail
Cantor Fitzgerald Forecasts CATX FY2026 Earnings - Defense World
Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Stocks Sharply Higher on a Better-Than-Expected US May Payroll Report - The Globe and Mail
151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Acquires 5,011 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Rating Increased to Moderate Buy at Royal Bank of Canada - Defense World
3 Promising Penny Stocks With Market Caps Over $90M - simplywall.st
Perspective Therapeutics (CATX) Price Target Raised by RBC Capital | CATX Stock News - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Scotiabank - The Globe and Mail
RBC Capital Boosts Price Target for Perspective Therapeutics (CA - GuruFocus
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kapitalisierung:
|
Volumen (24h):